Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05357404Active Not Recruiting

Age and Sex-Specific PREValence of AcqUirEd VALVular Heart DiseasE

Role: collaborator

NCT04024046Terminated

Uqora Supplements in Women With UTIs

Role: lead

NCT04103099Not ApplicableCompleted

Impact of HLNatural Immune Supplement on Colds

Role: lead

NCT04091555Not ApplicableCompleted

Evaluation of the Impact of the HL Natural, Inc. Tension Relief Product

Role: lead

NCT04153552Not ApplicableCompleted

Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn

Role: lead

All 5 trials loaded